Merav Fraenkel

Prof. Dr. Merav Fraenkel

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2013 in Endocrine-Related Cancer
Verified
Journal Article
Closed access
PDF file
MFMerav Fraenkel
Merav Fraenkel
MKM Kim
M Kim
AFAntongiulio Faggiano
Antongiulio Faggiano
WHW W de Herder
W W de Herder
GVG D Valk
G D Valk
Based on the current medical literature, the worldwide incidence of neuroendocrine tumours (NETs) seems to have increased; however, a systematic literature overview is lacking. This study aimed to collect all available data on the incidence of gastroenteropancreatic (GEP)-NETs and characteristics of population to establish their epidemiology. A sensitive MEDLINE search was carried out. The papers were selected via a cascade process that restricted the initial pool of 7991 articles to 33, using predefined inclusion and exclusion criteria. Original articles evaluating the incidence of sporadic GEP-NETs in regional, institutional and national registries were considered. The majority of data originated from the US National Cancer Institute Surveillance, Epidemiology and End Results database and from national cancer registries in Western Europe. Generally, because of the retrospective nature of existing databases the outcomes of studies might be biased, which hinders the drawing of firm conclusions. The age-adjusted incidence of GEP-NETs has increased steadily over the past four decades (1973–2007), increasing 3.65-fold in the USA and 3.8- to 4.8-fold in the UK. Incidence has changed variably from one anatomical site to another. The greatest increase in incidence occurred for gastric and rectal NETs, while the smallest increase occurred for small intestine NETs. There were gender and racial differences, which differed site by site and, in some cases, changed over time. The incidence rates (IRs) of GEP-NETs have increased significantly in the last 40 years. Data are only available from North America, Western Europe and Japan. A site-by-site analysis revealed that the IRs of some NETs increased more than those of others.

1 December 2012 in Best Practice & Research Clinical Gastroenterology
Verified
Journal Article
Closed access
MFMerav Fraenkel
Merav Fraenkel
MKM.K. Kim
M.K. Kim
AFAntongiulio Faggiano
Antongiulio Faggiano
GVG.D. Valk
G.D. Valk

31 May 2016 in Bone
Verified
Journal Article
Closed access
PDF file
ANAnat Nevo-Shor
Anat Nevo-Shor
SKSlava Kogan
Slava Kogan
BJBen-Zion Joshua
Ben-Zion Joshua
ABAnat Bahat-Dinur
Anat Bahat-Dinur
VNVictor Novack
Victor Novack
MFMerav Fraenkel
Merav Fraenkel

25 March 2018 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
RJR.S. Jallad
R.S. Jallad
ISIlan Shimon
Ilan Shimon
MFMerav Fraenkel
Merav Fraenkel
VMV. Medvedovsky
V. Medvedovsky
Amit AkirovAmit Akirov
Amit Akirov
MBM D Bronstein
M D Bronstein

5 August 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MFMerav Fraenkel
Merav Fraenkel
VNVictor Novack
Victor Novack
YLYair Liel
Yair Liel
MKMichael Koretz
Michael Koretz
ESEthel Siris
Ethel Siris
DGDavid B. Geffen
David B. Geffen
Previous studies have suggested an inverse relationship between bone mineral density (BMD) and breast cancer incidence. The primary objective of this study was to assess whether BMD is associated with risk of subsequent breast cancer occurrence in the female population of southern Israel. The electronic medical charts of women who underwent BMD at the Soroka Medical Center (SMC) between February 2003 and March 2011 were screened for subsequent breast cancer diagnoses. Women were divided by tertiles of BMD at 3 skeletal sites: lumbar spine (LS, L1–4), total hip (TH) and femoral neck (FN). The incidence of breast cancer was calculated. Of 15268 women who underwent BMD testing, 86 were subsequently diagnosed with breast cancer. Most women in the study were older than 50 years (94.2% and 92.7%, respectively; p = 0.597). Women who subsequently developed breast cancer had a higher mean body-mass index (BMI) (30.9±5.5 vs. 29.1±5.7 p = 0.004) and the mean BMD Z-score was significantly higher than in those without breast cancer for all 3 skeletal sites (LS: 0.36±1.58 vs. −0.12±1.42, p = 0.002; TH: 0.37±1.08 vs. 0.03±1.02, p = 0.002; FN: 0.04±0.99 vs. −0.18±0.94; p = 0.026). Women in the highest Z-score tertiles at the FN and TH had a higher chance of developing breast cancer compared to the lowest tertile; odds ratio of 2.15, 2.02, respectively (P = 0.004 and 0.01 respectively). No association was found between the BMD Z-score and the stage, histology, grade or survival from breast cancer. This study provides additional support for an inverse association between BMD and the risk of breast cancer.

23 May 2017 in Osteoporosis International
Verified
Journal Article
Closed access
PDF file
MFMerav Fraenkel
Merav Fraenkel
MYM. Yitshak-Sade
M. Yitshak-Sade
LBL. Beacher
L. Beacher
MCM. Carmeli
M. Carmeli
MMM. Mandelboim
M. Mandelboim
VNV. Novack
V. Novack